Alkermes plc. (ALKS)
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Address
CONNAUGHT HOUSE
DUBLIN 4, L2 00000
Founded
2011
Number of Employees
2,100
Website
http://www.alkermes.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | - | - | - | $85,336 | $85,336 |
| Average Price | - | - | - | - | - | - | - | - | - | - | $24.22 | $24.22 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | - | 3,522,879 | 3,522,879 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | - | 11.5% | 11.5% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | - | 7.4% | 7.4% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | - | 4.1% | 4.1% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | - | 64% | 50% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at ALKS make a trade.
Creating a free account takes less than one minute